---
title: "ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265988785.md"
datetime: "2025-11-14T21:54:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265988785.md)
  - [en](https://longbridge.com/en/news/265988785.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265988785.md)
generator: "portal-rs"
---

# ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.63.

EBIT: As of FY2025 Q3, the actual value is USD -1.149 M.

### Segment Revenue

-   **Research and Development Services**: Revenue was $0 for the three and nine months ended September 30, 2025, compared to $183,000 for the same periods in 2024, reflecting a decrease due to the absence of revenue from research and development services performed for Celltrion related to ABP-102 development.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended September 30, 2025, was $1.657 million, a decrease from $2.093 million in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $8.528 million, compared to $3.897 million in 2024, indicating a significant increase in losses.
-   **Research and Development Expenses**: Decreased to $243,000 for the three months ended September 30, 2025, from $642,000 in the same period in 2024. For the nine months ended September 30, 2025, expenses were $881,000, down from $2.469 million in 2024, primarily due to personnel furloughs and reduced activities.
-   **General and Administrative Expenses**: Decreased to $1.093 million for the three months ended September 30, 2025, from $1.472 million in 2024. For the nine months ended September 30, 2025, expenses increased to $5.674 million from $4.864 million in 2024, mainly due to increased costs of operating as a public company.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used was $5.386 million, slightly higher than $5.215 million in 2024.
-   **Net Cash Provided by Financing Activities**: Decreased to $2.711 million for the nine months ended September 30, 2025, from $4.495 million in 2024, reflecting lower proceeds from debt issuance and other financing activities.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to initiate clinical trials for ABP-102 in the first half of 2026, focusing on HER2+ solid tumors, and for ABP-201, contingent on future funding availability.
-   **Going Concern**: There is substantial doubt about the company’s ability to continue as a going concern within one year after the date the financial statements are issued, due to insufficient cash to operate for at least 12 months. The company plans to seek additional funding through equity and debt financings, collaboration agreements, and research grants.

### Related Stocks

- [ABPWW.US](https://longbridge.com/en/quote/ABPWW.US.md)

## Related News & Research

- [Why is your gold waiting on a speech?](https://longbridge.com/en/news/296733808.md)
- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Nvidia Earnings: Wall Street Expects Growth to Slow in Q2 — Dan Niles Says Hyperscalers Are Spending Like Never Before](https://longbridge.com/en/news/296822352.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)
- [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**